Trial Profile

An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Somavaratan (Primary)
Indications Growth disorders; Somatotropin deficiency
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms VITAL
Sponsors Versartis

Most Recent Events

27 Jul 2017 According to a Versartis media release, data will be presented at the 10th Annual International Joint Meeting of Pediatric Endocrinology (IMPE) Sep 2017.
04 Apr 2017 Results of an ad hoc analysis on preliminary data assessing correlation between baseline IGF-I, dose, and response presented at The 99th Annual Meeting of the Endocrine Society
04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com